SURPASS-CVOT: tirzepatide vs dulaglutide negli outcome CV nel T2DM - A cura di A. Cignarelli, M. Marassi e G. A. Silveriii

from Le Voci del Journal Club SID · host Società Italiana Diabetologia

SURPASS-CVOT: duello tirzepatide versus dulaglutide sugli outcome cardiovascolari nel T2DM - A cura di Angelo Cignarelli, Marella Marassi e Giovanni Antonio Silverii Articolo di riferimento: Stephen J. Nicholls, M.B., B.S., Ph.D., Imre Pavo, M.D., Deepak L. Bhatt, M.D., M.P.H., John B. Buse, M.D., Ph.D., Stefano Del Prato, M.D., Steven E. Kahn, M.B., Ch.B., A. Michael Lincoff, M.D., +20, for the SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. Published December 17, 2025. N Engl J Med 2025;393:2409-2420. DOI: https://www.nejm.org/doi/10.1056/NEJMoa2505928

Episode metadata supplied by the publisher feed · Published May 22, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

SURPASS-CVOT: tirzepatide vs dulaglutide negli outcome CV nel T2DM - A cura di A. Cignarelli, M. Marassi e G. A. Silveriii

0:00 3:23

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Le Voci del Journal Club SID?

This episode is 3 minutes long.

When was this Le Voci del Journal Club SID episode published?

This episode was published on May 22, 2026.

Can I download this Le Voci del Journal Club SID episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!